Martinsried/Munich, 4 September 2015. Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation in four upcoming investment and scientific conferences:
- 4th European Congress of Immunology
Date: 6 - 9 September 2015
Location: Vienna, Austria
Poster presentation on 9 September, 9:45 - 11:15 am (MEST): "Induction of memory T cell subpopulations for usage in adoptive T cell therapy" - Medigene's cooperation partner Helmholtz Zentrum Munich presents data generated in a joint SFB cooperation project.
- CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival
Date: 16 - 19 September 2015
Location: New York, USA
Poster presentation on 16 September, 7 - 9 pm (EDT): "Expitope: A webserver for TCR candidate validation"
- HPV 2015 - 30th International Papillomavirus Conference
Date: 17 - 21 September 2015
Location: Lisbon, Portugal
Poster presentation on 18 - 20 September, 11:30 am - 1 pm (WEST): "Durable immunity to oncogenic HPV elicited by adjuvanted recombinant adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes"
- Baader Investment Conference
Date: 22. - 24. September 2015
Location: Munich, Germany
Company presentation on 22 September, 12:15 pm (MEST)
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical and preclinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit www.medigene.com.
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
To unsubscribe from the press release distribution list, please visit: www.medigene.de/unsubscribe